f Less is More in Antithrombotic Therapy for Durable Left Ventricular Assist Devices

References

1. BrownM.T. BortfeldK.S. SperlingL.S. WengerN.K. Redefining the roles of aspirin across the spectrum of cardiovascular disease prevention.Curr. Cardiol. Rev.2023196922 37132104
   [Google Scholar]
2. ConsoloF. LucchettiR.M. TramontinC. LapennaE. PappalardoF. Do we need aspirin in HeartMate 3 patients?Eur. J. Heart Fail.201921681581710.1002/ejhf.1468 30983057
   [Google Scholar]
3. OttoC.M. NishimuraR.A. BonowR.O. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.Circulation20211435e72e227 33332150
   [Google Scholar]
4. ShahP. TantryU.S. BlidenK.P. GurbelP.A. Bleeding and thrombosis associated with ventricular assist device therapy.J. Heart Lung Transplant.201736111164117310.1016/j.healun.2017.05.008 28579115
   [Google Scholar]
5. Del Rio-PertuzG. NairN. Gastrointestinal bleeding in patients with continuous‐flow left ventricular assist devices: A comprehensive review.Artif. Organs2023471122310.1111/aor.14432 36334280
   [Google Scholar]
6. TedfordR.J. LeaccheM. LortsA. DrakosS.G. PaganiF.D. CowgerJ. Durable mechanical circulatory support.J. Am. Coll. Cardiol.202382141464148110.1016/j.jacc.2023.07.019 37758441
   [Google Scholar]
7. MehraM.R. NetukaI. UrielN. Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure.JAMA2023330222171218110.1001/jama.2023.23204 37950897
   [Google Scholar]
8. AgarwalN. MahmoudA.N. PatelN.K. Meta-analysis of aspirin versus dual antiplatelet therapy following coronary artery bypass grafting.Am. J. Cardiol.20181211324010.1016/j.amjcard.2017.09.022 29122278
   [Google Scholar]
9. ArnettD.K. BlumenthalR.S. AlbertM.A. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.Circulation201914011e563e59510.1161/CIR.0000000000000677 30879339
   [Google Scholar]
10. DavidsonK.W. BarryM.J. MangioneC.M. Aspirin use to prevent cardiovascular disease.JAMA2022327161577158410.1001/jama.2022.4983 35471505
    [Google Scholar]
11. GragnanoF. CaoD. PirondiniL. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events.J. Am. Coll. Cardiol.20238228910510.1016/j.jacc.2023.04.051 37407118
    [Google Scholar]
12. KnijnikL. FernandesM. RiveraM. Meta-analysis of duration of dual antiplatelet therapy in acute coronary syndrome treated with coronary stenting.Am. J. Cardiol.2021151252910.1016/j.amjcard.2021.04.014 34049672
    [Google Scholar]
13. O’DonoghueM.L. MurphyS.A. SabatineM.S. The safety and efficacy of aspirin discontinuation on a background of a P2Y 12 inhibitor in patients after percutaneous coronary intervention.Circulation2020142653854510.1161/CIRCULATIONAHA.120.046251 32551860
    [Google Scholar]